For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | 11,038 | - | 2,820 |
| Cost of revenues | - | 2,388 | - | - |
| Research and development | 19,983 | 21,711 | 17,808 | 17,133 |
| General and administrative | 4,377 | 5,234 | 5,653 | 5,437 |
| Total costs and operating expenses | - | 29,333 | 23,461 | 22,570 |
| Total operating expenses | 24,360 | - | - | - |
| Loss from operations | -24,360 | -18,295 | -23,461 | -19,750 |
| Interest and investment income, net | 457 | 600 | 774 | 995 |
| Sublease income | 631 | 692 | 684 | 684 |
| Total other income, net | 1,088 | 1,292 | 1,458 | 1,679 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest, total | - | -17,569* | -22,003 | -18,071 |
| Income tax expense (benefit) | - | 537* | - | 283 |
| Net loss | -23,272 | -18,106 | -22,003 | -18,354 |
| Net unrealized loss on marketable debt securities | -53 | -16 | 74 | -54 |
| Other comprehensive loss | -53 | -16 | 74 | -54 |
| Comprehensive loss | -23,325 | -18,122 | -21,929 | -18,408 |
| Basic EPS | -0.37 | -0.287 | -0.35 | -0.3 |
| Diluted EPS | -0.37 | -0.287 | -0.35 | -0.3 |
| Basic Average Shares | 63,469,850 | 63,047,504 | 62,557,386 | 61,918,826 |
| Diluted Average Shares | 63,469,850 | 63,047,504 | 62,557,386 | 61,918,826 |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)